Tell us
what you really want
from your fertility clinic abroad…
Complete a 5-minute, anonymous survey to help others find the right clinic abroad, and we'll donate €1 to a fertility society for each submission.

Endometrium Optimization: ERA, EMMA, ALICE & New Tests

Medically verified
Harry Karpouzis, MD
Fertility Specialist; Founder & Scientific Director, IVF Pelargos Fertility Group
From this event you will find out:
  • Why checking the embryo comes before ordering more lining tests
  • What a lining below 7 mm means for transfer success
  • Why ERA timing tests aren’t a routine answer
  • When inflammation testing deserves a closer look
  • Whether a different transfer protocol could matter more than another biopsy
  • Who may and may not benefit from ERA, EMMA and ALICE

Table of Contents - Quick Navigation

A failed embryo transfer does not automatically mean the womb lining needs more testing: the embryo remains the main reason a transfer does not work, a distinction central to the approach of Dr Harry Karpouzis, Founder & Scientific Director at IVF Pelargos Fertility Group.

Hosted by Carly Garrett, Reflexologist and Fertility Coach, UK.

Start With the Embryo, Not a Shopping List of Tests

After an unsuccessful transfer, it is understandable to want every possible investigation before trying again. Tests promising to assess implantation timing, bacteria or immune activity can seem like a route to a clearer answer. But their usefulness depends on what has already been checked—and whether the result would meaningfully change treatment.

The endometrium, the lining of the womb, is the second most important factor in a failed transfer after the embryo itself. Its thickness, inflammation, immune environment and readiness for implantation can all matter. That does not mean every patient needs every available endometrial test.

Previous transfers involving untested embryos leave a particular uncertainty: even if a lining problem is found later, it may not explain those earlier failures. Treating an identified infection may be appropriate, but it cannot establish that the infection caused the transfers to fail. The embryo could still have been the reason.

The pathway used at IVF Pelargos Fertility Group therefore begins with reviewing the embryo, including PGT-A, before moving through possible endometrial causes. More specialised investigations are mainly considered for recurrent implantation failure, rather than straightforward IVF treatment. The definition used in this approach is more than three failed transfers, or more than two failed transfers involving euploid embryos.

Check the Basics Before Looking for Hidden Causes

An advanced test is not a substitute for reviewing the transfer protocol, lifestyle factors and the condition of the womb. Endometrial thickness and progesterone levels should be assessed before transfer. Structural problems also need attention before a timing or immune test becomes the focus.

The preferred lining thickness in this approach is more than 8 mm, although more than 7 mm can be acceptable. When the lining is less than 7 mm, the chances of success are reduced. A measurement early in the cycle, when the lining is still developing, does not provide the same information as an assessment closer to transfer.

Hysteroscopy allows the womb cavity to be examined and targeted biopsies to be taken under camera guidance. It has a central role in the clinic’s investigation of recurrent implantation failure, although it is not a routine procedure for every patient starting IVF. Scar tissue, fibroids, polyps and septa are among the problems that should be excluded, with hysteroscopic correction considered when a cavity problem is found.

Other conditions can affect implantation without being explained by a receptivity test. Three-dimensional ultrasound can help assess fibroids and adenomyosis, while hydrosalpinx may require the affected tubes to be clipped or removed. The practical priority is to identify problems that can change the treatment plan, rather than moving immediately to less established tests.

When Inflammation and Bacteria Deserve Investigation

A lining that appears suitable in thickness may still have inflammation. Chronic endometritis is a chronic, low-grade inflammation within the womb lining, and it is different from endometriosis. It may be present in about 10% to 30% of women with repeated implantation failure.

That figure makes chronic endometritis worth considering in selected patients, but it does not settle the question of how much testing and treatment improve IVF outcomes. Some studies have shown higher pregnancy rates after treatment, while others have not shown an increase in live birth rate. The evidence remains conflicting, so testing is generally reserved for recurrent implantation failure after more important causes have been excluded.

Evaluation can combine hysteroscopy with targeted biopsies. The biopsy material may be assessed using molecular tests such as ALICE, or through culture, PCR or CD138 histology. These investigations look for evidence of chronic infection or inflammation rather than simply measuring the lining.

A related assessment looks at the endometrial microbiome, the bacterial environment within the womb lining. Tests such as Emma examine whether Lactobacillus is dominant, which is considered the ideal environment in this approach. A non-Lactobacillus-dominant endometrium has been linked with lower implantation and live birth rates, although that association does not prove it caused an individual patient’s failed transfer.

The distinction matters because infection testing and microbiome testing can lead to different treatments. Identified chronic endometritis calls for antibiotics, whereas low Lactobacillus may lead to probiotics in selected cases. An abnormal result should be interpreted alongside the embryo history and the rest of the investigation, not treated as a complete explanation on its own.

What Treatment—and Retesting—Can Actually Tell You

When testing identifies a specific organism, antibiotic treatment can be targeted to it. Metronidazole may be used for Gardnerella, for example, while doxycycline may be used for Ureaplasma. These are treatment decisions for the clinical team, not a reason to begin antibiotics before an assessment.

The timing of the biopsy matters too. Taking antibiotics beforehand can make the result inaccurate. Patients should therefore tell their clinic about recent antibiotic use before arranging infection or microbiome testing.

After treatment, another decision arises: should the biopsy be repeated before transfer? Although these tests may recommend rechecking, the evidence supporting routine repeat testing is not strong. At IVF Pelargos Fertility Group, correctly identified and treated infections are not routinely followed by another biopsy.

That approach also takes account of the financial burden and delay of repeat testing, particularly for patients travelling from abroad. Retesting remains an option rather than an obligation. The useful discussion is whether another result would change the next step, rather than assuming that a second biopsy is always necessary—or never worthwhile.

Receptivity Testing: A Timing Question, Not a Universal Answer

The implantation window is the period when the lining is ready for an embryo to implant. In women with regular 28-day cycles, it usually falls between days 19 and 22. A transfer outside that window may reduce the chance of implantation.

In a medicated frozen embryo transfer cycle, estrogen is given first, followed by progesterone. Implantation is expected around 120 hours of progesterone exposure—five full days after progesterone starts. A small percentage of women may have a window shifted earlier or later.

Endometrial receptivity testing, including ERA, attempts to identify that timing. Testing takes place in a mock cycle, with a biopsy collected when the transfer would normally occur. The result may classify the lining as prereceptive, receptive or postreceptive, allowing the transfer timing to be adjusted.

The appeal is clear: a personalised timetable seems like an answer to an otherwise unexplained failure. But the evidence supporting ERA is weakening, and it should not be used routinely. It may offer a small benefit in selected women with recurrent implantation failure, particularly when good-quality or tested embryos have failed to implant, and more important explanations have been ruled out.

The testing protocol also needs to match the planned transfer protocol as closely as possible. A result obtained in a medicated cycle should not simply be assumed to apply unchanged to a natural cycle. A 120-hour result is not itself abnormal; it corresponds to the expected timing in a medicated cycle.

Immune Testing Belongs Later in the Investigation

Reproductive immunology is another area where the promise of personalised care needs to be balanced against uncertain evidence. It may be relevant to some patients with recurrent implantation failure or recurrent miscarriage. It is not a reason to order a broad immune panel for everyone undergoing embryo transfer.

Some investigations look for systemic conditions, including antiphospholipid syndrome, which can be identified through blood tests and treated with relevant medication. Hashimoto’s thyroid disease is also sometimes associated with implantation problems. These conditions sit alongside, rather than replace, the assessment of embryos and the womb.

More specialised testing may examine natural killer cells, their activity and aspects of immune balance. In this approach, those investigations are reserved for selected patients whose more common causes have already been checked. Treatment may then be individualised, but the evidence for reproductive immune testing and treatment remains conflicting.

The same caution applies to proposed therapies. Evidence for IVIG is very conflicting, and the clinic does not use IVIG or LIT. The availability of an immune test or treatment does not, by itself, establish that it will improve the outcome of the next transfer.

Sometimes the Better Next Step Is a Different Protocol

Not every unsuccessful transfer calls for another test. Endometriosis and adenomyosis may affect implantation, and treatment may involve suppressing the disease before transfer. Neither condition should automatically be accepted as the sole explanation for previous failures.

For a persistently thin lining, treatments such as PRP or G-CSF may be considered, but there is no conclusive evidence supporting them. Endometrial scratching also lacks supporting evidence and is not used for all patients. These options should be discussed with their uncertainty made explicit, rather than presented as established solutions.

The transfer protocol itself may also deserve reconsideration. After investigations and treatment, the clinic sometimes returns to a natural approach, transferring in a properly assessed spontaneous ovulation cycle rather than a medicated cycle. This can work in some cases, but in others implantation still does not occur, and the cause remains unknown.

Before agreeing to further investigations, patients can bring three practical questions to their appointment:

  • What more common causes have already been checked?
  • How would this test result change my treatment or transfer protocol?
  • What is the evidence that the proposed treatment improves outcomes, and would retesting change the plan?

These questions help keep the discussion focused on decisions rather than the number of tests available. They also make room to consider the cost and delay of additional biopsies. The aim is a coherent plan, not an exhaustive search without a clear next step.

Final Thoughts

Optimising the endometrium is not about making every patient undergo the same battery of tests. It means checking the embryo and the fundamentals of transfer first, addressing identifiable problems, and reserving more uncertain investigations for patients whose history gives a reason to consider them. A finding can be worth treating without proving that it explains every previous failure.

A careful, stepwise approach leaves room for hope, but no test can promise an answer in every case. Sometimes the next useful step is targeted treatment; sometimes it is a revised transfer protocol rather than another biopsy. The most valuable plan is one that makes clear what is known, what remains uncertain and why each proposed step is worth taking.

Endometrium Optimization: ERA, EMMA, ALICE & New Tests | FAQ

Can metronidazole treatment improve the chances of implantation after eight failed transfers with untested embryos?

After 8 transfers with untested embryos, it is impossible to know exactly why implantation failed. The embryos themselves could have been the reason. If the current embryo is euploid, that is the right step: a euploid embryo can offer very good chances of implantation, depending on its grading.

If Emma/ALICE testing identifies anaerobic bacteria that metronidazole can treat, the infection should be treated. Those bacteria cannot be confirmed as the cause of the previous failures, but they still need treatment because they can sometimes be associated with failed implantation.

Should an endometrial biopsy or microbiome test be repeated after treatment?

The test recommends rechecking, but this is not obligatory. Once the bacteria have been identified and treated appropriately, repeating the biopsy can add financial burden and delay. It is also inconvenient for patients travelling from abroad for treatment.

The evidence supporting rechecking is not strong. At Pelargos IVF, we provide the correct treatment without routinely repeating the biopsy.

Who should consider ERA, Emma, or ALICE testing?

Straightforward IVF patients should not undergo these tests routinely. They are considered mainly for recurrent implantation failure, defined here as three or more failures, or two failures with euploid embryos.

There are grounds for investigating these patients, particularly when euploid embryos are available and should not be put at risk. The same principle applies to ERA testing: these tests are for a specific group with previous implantation failures, not routine IVF patients.

What should be investigated when recurrent implantation failure has no clear cause?

The next steps depend on how thoroughly the case has already been investigated. A stepwise evaluation includes confirming that there is a euploid embryo, performing hysteroscopy, investigating chronic endometritis and the microbiome, assessing immunology and the implantation window, and checking progesterone levels.

If nothing is found, returning to a natural approach, with transfer on spontaneous ovulation, is often preferred. After investigations and treatments, switching back to a properly checked natural ovulation cycle sometimes works. In other cases, implantation never occurs, and the cause remains unknown.

How can the endometrium be prepared before transfer in patients with endometriosis?

Endometriosis can affect implantation. The usual approach is to suppress the disease as much as possible before transfer.

The preferred protocols use GnRH agonists before injections such as Gonapeptil, Arvacap, and Zoladex, with the aim of suppressing the endometrium as much as possible. The same approach applies to adenomyosis before embryo transfer.

Other causes of implantation failure should still be investigated. Endometriosis does not necessarily explain the failures on its own.

What testing is appropriate with 2 euploid embryos, endometriosis, PCOS, and a planned modified natural transfer?

An endometrial measurement on cycle day 5 does not provide important information because the lining is usually thinner then. The follicle pattern described also suggests polycystic ovaries.

If endometriosis is significant, down-regulation may be worth considering instead of a modified natural cycle; discuss this with the treating doctor. With two valuable euploid embryos, microbiome and chronic endometritis testing is reasonable, particularly because endometriosis is often associated with chronic endometritis. Hysteroscopy is preferred over 3D ultrasound to obtain targeted biopsies.

The lining should be allowed to increase properly before transfer. If it previously became thick enough, down-regulation may be possible. If it tends not to thicken sufficiently alongside polycystic ovaries, a modified cycle may be the best option. Immunology testing is not recommended here without a history of miscarriage or recurrent implantation failure.

Can a 120-hour ERA result from a medicated or blocked cycle be used for a natural-cycle frozen transfer?

A 120-hour ERA result is not abnormal. Ideally, testing should use the same protocol that will ultimately be used for embryo transfer.

If a natural frozen cycle is chosen, transfer can take place at the relevant timing: LH plus 7. In a medicated cycle, transfer is five days after starting progesterone. Ideally, all these tests should be performed using the intended transfer protocol.

Should a biopsy be repeated after ciprofloxacin treatment for a small amount of streptococcus?

Ciprofloxacin 500 mg twice a day for 10 days is an appropriate treatment. Ten days is adequate; treatment usually lasts 10 to 14 days.

Antibiotics are often combined with probiotics because they can sometimes change the vaginal and endometrial flora. The biopsy is not usually repeated at the clinic, although repeating it remains an option for the patient before the planned transfer next cycle. The test itself usually assesses this issue.

Fertility Knowledgebase - Related Events

Related Fertility Questions - Answered by Various Experts

What is a good uterine lining thickness for implantation?

Lyubov Mykhaylyshyn, MD, Phd
Gynaecologist

+ 1 more answers

Read More »

How is endometrium prepared for implantation?

Lyubov Mykhaylyshyn, MD, Phd
Gynaecologist

+ 4 more answers

Read More »

What are implantation cramps?

Santiago Eduardo Novoa, MD
Gynaecologist

+ 2 more answers

Read More »

Why do PGT-A / PGS embryos fail?

Dimitra Christopikou, Clinical Laboratory Geneticist
Geneticist

Read More »

What causes implantation failure in IVF?

Dimitris Papanikolaou, MD
Gynaecologist

Read More »

Does endometrial scratch help implantation?

Lyubov Mykhaylyshyn, MD, Phd
Gynaecologist

+ 1 more answers

Read More »